What side effects are associated with this type of intervention?

Common treatments for Non-Small Cell Lung Cancer (NSCLC) involving immune checkpoint inhibitors and targeted therapies, such as pembrolizumab, nivolumab, and ipilimumab, often result in a range of side effects. These can include immune-related adverse events like skin reactions, endocrine disorders, and pneumonitis. Other frequent side effects are fatigue, diarrhea, and infusion-related reactions. Severe adverse events, though less common, can include pneumonia, acute kidney injury, and severe diarrhea. The combination of these therapies with chemotherapy can also increase the incidence of hematologic toxicities such as anemia and neutropenia.

What prior FDA approvals exist?

Several immune checkpoint inhibitors and targeted therapies have received FDA approval for the treatment of Non-Small Cell Lung Cancer (NSCLC). Pembrolizumab, often combined with chemotherapy, has shown significant improvements in overall survival (OS) and progression-free survival (PFS) in various trials, such as KEYNOTE-407. Nivolumab, another immune checkpoint inhibitor, is approved for advanced NSCLC after failure of prior platinum-based chemotherapy. Atezolizumab, combined with chemotherapy and bevacizumab, has also been approved for advanced nonsquamous NSCLC, demonstrating improved PFS and OS in the IMpower 150 trial. These approvals highlight the efficacy of combining immune checkpoint inhibitors with chemotherapy in treating NSCLC.

What other types of research exist?

Promising novel alternatives to Volrustomig for NSCLC patients include: 1) Pembrolizumab plus chemotherapy, which has shown improved overall survival and progression-free survival in multiple trials. 2) Nivolumab plus ipilimumab, with or without chemotherapy, which has demonstrated efficacy in various settings. 3) Avelumab plus axitinib, which has shown superior response rates and progression-free survival in metastatic renal cell carcinoma and may be applicable to NSCLC. These treatments have demonstrated significant clinical benefits and are likely to be considered in 2024.

← Back to Search

Monoclonal Antibodies

Volrustomig + Chemotherapy for Advanced Non-Small Cell Lung Cancer (eVOLVE-Lung02 Trial)

Q: What is the mechanism of action of this treatment?

Common treatments for Non-Small Cell Lung Cancer (NSCLC) include immune checkpoint inhibitors and targeted therapies. Immune checkpoint inhibitors, like pembrolizumab and nivolumab, block proteins such as PD-1 or PD-L1, enabling the immune system to better recognize and attack cancer cells. Targeted therapies focus on specific genetic mutations or proteins that drive cancer growth, such as EGFR or ALK inhibitors, and work by disrupting the molecular pathways essential for tumor development. These treatments are significant for NSCLC patients as they offer personalized and potentially more effective options based on the unique characteristics of their cancer.

Phase 3

Recruiting

Research Sponsored by AstraZeneca

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to approximately 6 years

Awards & highlights

eVOLVE-Lung02 Trial Summary

This trial tests if a new drug combo is better than an existing one for lung cancer patients with PD-L1 < 50%.

Who is the study for?

This trial is for adults with stage IV non-small cell lung cancer (NSCLC) without certain genetic mutations or rearrangements. Candidates should not have a history of other cancers within the last 2 years, except some skin cancers and localized cancers that were treated. They must not have brain metastases requiring steroids or mixed NSCLC histology.Check my eligibility

What is being tested?

The study compares two treatments: Volrustomig combined with chemotherapy versus Pembrolizumab (also known as Keytruda) with chemotherapy in patients whose tumors express PD-L1 <50%. The goal is to see which treatment works better for this specific group of lung cancer patients.See study design

What are the potential side effects?

Possible side effects include immune-related reactions, fatigue, nausea, hair loss from chemotherapy, and potential allergic reactions to the drugs being tested. Side effects can vary based on individual patient health and response to treatment.

eVOLVE-Lung02 Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to approximately 6 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to approximately 6 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 6 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Overall Survival (OS), in PD-L1-negative participants.

Progression-Free Survival (PFS) (using BICR assessments according to RECIST 1.1)

Secondary outcome measures

Concentration of volrustomig in serum and PK parameters

Duration of Response (DoR)

+7 more

eVOLVE-Lung02 Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Arm 1Experimental Treatment4 Interventions

Volrustomig plus histology-specific chemotherapy (carboplatin plus either pemetrexed or paclitaxel) via iv infusion

Group II: Arm 2Active Control4 Interventions

Pembrolizumab plus histology-specific chemotherapy (carboplatin plus either pemetrexed or paclitaxel) via iv infusion

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Carboplatin

2014

Completed Phase 3

~6670

Paclitaxel

2011

Completed Phase 4

~5380

Pemetrexed

2014

Completed Phase 3

~5250

Do I qualify?Apply below to find out

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Common treatments for Non-Small Cell Lung Cancer (NSCLC) include immune checkpoint inhibitors and targeted therapies. Immune checkpoint inhibitors, like pembrolizumab and nivolumab, block proteins such as PD-1 or PD-L1, enabling the immune system to better recognize and attack cancer cells. Targeted therapies focus on specific genetic mutations or proteins that drive cancer growth, such as EGFR or ALK inhibitors, and work by disrupting the molecular pathways essential for tumor development. These treatments are significant for NSCLC patients as they offer personalized and potentially more effective options based on the unique characteristics of their cancer.

Find a Location

Who is running the clinical trial?

AstraZenecaLead Sponsor

4,293 Previous Clinical Trials

288,619,504 Total Patients Enrolled

Media Library

Pembrolizumab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05984277 — Phase 3

Non-Small Cell Lung Cancer Research Study Groups: Arm 1, Arm 2

Non-Small Cell Lung Cancer Clinical Trial 2023: Pembrolizumab Highlights & Side Effects. Trial Name: NCT05984277 — Phase 3

Pembrolizumab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05984277 — Phase 3

~600 spots leftby May 2028

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.